Skip to main content
. 2019 Feb 20;33(9):2276–2290. doi: 10.1038/s41375-019-0416-x

Fig. 4.

Fig. 4

Kaplan–Meier estimates of overall survival, leukemia-free survival, and duration of response in MDS patients treated with azacitidine and lenalidomide. a Patients are stratified according to the presence of SRSF2 mutation (SRSF2) or the absence of SRSF2 mutation (NO MUT). b Patients are stratified according to the presence of our 3-inositide gene mutation (CLUSTER) or the absence of our 3-inositide gene mutation (NO MUT). *p < 0.05 CLUSTER vs NO MUT